Deep Remission Tied to RA Control
At 5 years, 63% of patients in the CliDR group maintained sustained remission compared with 38% in the non-CliDR group.
By
Andrea Surnit
May 6, 2026
Clinical Scorecard: Deep Remission Tied to RA Control
At a Glance
Category Detail
Condition Rheumatoid Arthritis Key Mechanisms Clinical deep remission (CliDR) reflects complete absence of clinically detectable joint inflammation. Target Population Patients with rheumatoid arthritis achieving remission based on DAS28-CRP. Care Setting Single-center observational cohort study.
Key Highlights
63% of patients in the CliDR group maintained sustained remission at 5 years. Relapse occurred in 12 of 32 patients in the CliDR group versus 70 of 113 in the non-CliDR group. Tapering was associated with an 8.5-fold higher relapse hazard in non-CliDR patients. Guideline-Based Recommendations
Diagnosis
Use DAS28-CRP for assessing remission in rheumatoid arthritis. Management
Consider achieving clinical deep remission (CliDR) for better long-term outcomes. Monitoring & Follow-up
Regular DAS28-CRP assessments to evaluate remission status. Risks
Increased relapse risk associated with treatment tapering in non-CliDR patients. Patient & Prescribing Data
Patients with rheumatoid arthritis, predominantly anti-CCP positive.
CliDR may provide additional prognostic information for medication tapering decisions.
Clinical Best Practices
Aim for clinical deep remission to improve sustained remission rates. Evaluate tapering strategies carefully in patients who have achieved CliDR. Related Resources & Content
